Oncotarget

Research Papers:

Interfering with the interaction between ErbB1, nucleolin and Ras as a potential treatment for glioblastoma

Yona Goldshmit, Sari Schokoroy Trangle, Yoel Kloog and Ronit Pinkas-Kramarski _

PDF  |  HTML  |  Order a Reprint

Oncotarget. 2014; 5:8602-8613. https://doi.org/10.18632/oncotarget.2343

Metrics: PDF 1207 views  |   HTML 1770 views  |   ?  


Abstract

Yona Goldshmit1,2,*, Sari Schokoroy Trangle1,*, Yoel Kloog1 and Ronit Pinkas-Kramarski1

Department of Neurobiology, Tel-Aviv University, Ramat-Aviv, Israel

Australian Regenerative Medicine Institute, Monash University, Australia

* These authors contributed equally to this work

Correspondence:

Ronit Pinkas-Kramarski, email:

Keywords: nucleolin, Ras, ErbB1, FTS, AS1411, signal transduction

Received: July 10, 2014 Accepted: August 11, 2014 Published: August 12, 2014

Abstract

The three oncogenes, ErbB receptors, Ras proteins and nucleolin may contribute to malignant transformation. Previously, we demonstrated that nucleolin could bind both Ras protein and ErbB receptors. We also showed that the crosstalk between the three proteins facilitates anchorage independent growth and tumor growth in nude mice, and that inhibition of this interaction in prostate and colon cancer cells reduces tumorigenicity. In the present study, we show that treatment with Ras and nucleolin inhibitors reduces the oncogenic effect induced by ErbB1 receptor in U87-MG cells. This combined treatment enhances cell death, reduces cell proliferation and cell migration. Moreover, we demonstrate a pivotal role of nucleolin in ErbB1 activation by its ligand. Nucleolin inhibitor prevents EGF-induced receptor activation and its downstream signaling followed by reduced proliferation. Furthermore, inhibition of Ras by Salirasib (FTS), mainly reduces cell viability and motility. The combined treatment, which targets both Ras and nucleolin, additively reduces tumorigenicity both in vitro and in vivo. These results suggest that targeting both nucleolin and Ras may represent an additional opportunity for inhibiting cancers, including glioblastoma, that are driven by these oncogenes.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 2343